Pharmacovigilance for rare diseases: a bibliometrics and knowledge-map analysis based on web of science
Ocular Surface Regeneration by Limbal Stem Cells Therapies: State of the Art, Challenges, and Perspectives
16 September 2023
Next-generation sequencing in dermatology
29 September 2023

Orphanet J Rare Dis. 2023 Sep 26;18(1):303. doi: 10.1186/s13023-023-02915-y. PMID: 37752556.

Pharmacovigilance for rare diseases: a bibliometrics and knowledge-map analysis based on web of science

Authors: Mengdan Xu 1 2Guozhi Li 3Jiazhao Li 4Huiyu Xiong 5Suzhen He 6

Affiliation:

  1. School of Clinical Pharmacy, Guangdong Pharmaceutical University, Guangzhou, Guangdong, China. xumengdan716@gdpu.edu.cn.
  2. NMPA Key Laboratory for Technology Research and Evaluation of Pharmacovigilance, Guangzhou, Guangdong, China. xumengdan716@gdpu.edu.cn.
  3. NMPA Key Laboratory for Technology Research and Evaluation of Pharmacovigilance, Guangzhou, Guangdong, China.
  4. School of Clinical Pharmacy, Guangdong Pharmaceutical University, Guangzhou, Guangdong, China.
  5. Center for ADR Monitoring of Guangdong, Guangzhou, Guangdong, China.
  6. The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.

Abstract:

Objectives: The aims of this paper is to search and explore publications in the field of pharmacovigilance for rare diseases and to visualize general information, research hotspots, frontiers and future trends in the field using the bibliometric tool CiteSpace to provide evidence-based evidence for scholars.

Methods: We searched the Web of Science Core Collection (WoSCC) for studies related to pharmacovigilance for rare diseases, spanning January 1, 1997-October 25, 2022. CiteSpace software was utilized to discuss countries/regions, institutions, authors, journals, and keywords.

Results: After screening, a total of 599 valid publications were included in this study, with a significant upward trend in the number of publications. These studies were from 68 countries/regions with the United States and the United Kingdom making the largest contributions to the field. 4,806 research scholars from 493 institutions conducted studies on pharmacovigilance for rare diseases. Harvard University and University of California were the top two productive institutions in the research field. He Dian of the Affiliated Hospital of Guizhou Medical University and Peter G.M. Mol of the University of Groningen, The Netherlands, were the two most prolific researchers. The Cochrane Database of Systematic Reviews and the New England Journal of Medicine were the journals with the highest number of articles and co-citation frequency respectively. Clinical trial, therapy and adverse event were the top three most cited keywords.

Conclusions: Based on keywords co-occurrence analysis, four research topics were identified: orphan drug clinical trials, postmarketing ADR surveillance for orphan drugs, rare diseases and orphan drug management, and diagnosis and treatment of rare diseases. Immune-related adverse reactions and benefit-risk assessment of enzyme replacement therapy were at the forefront of research in this field. Treatment outcomes, early diagnosis and natural history studies of rare diseases may become hotspots for future research.

Keywords: CiteSpace; Knowledge-map; Orphan drugs; Pharmacovigilance; Rare diseases; Research hotspots.

Download: https://ojrd.biomedcentral.com/articles/10.1186/s13023-023-02915-y